Results 1 to 10 of about 4,407 (134)

<i>In vitro</i> comparison of the effects of abelacimab, dalteparin, and apixaban on catheter-induced clotting and thrombin generation. [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Abelacimab is a fully human monoclonal antibody that binds factor XI, blocking its activation and activity. It is being compared with apixaban and dalteparin in patients with cancer-associated venous thromboembolism.
Ruiqi Yin, Xinyi Guo, James C. Fredenburgh, Jeffrey I. Weitz   +3 more
doaj   +2 more sources

Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: For women with antiphospholipid syndrome (APS) and placenta-mediated complications, the efficacy of heparin during subsequent pregnancies is uncertain.
Valérie L.B.I. Jansen, Hanke M.G. Wiegers, Dorien M. Salet, Thijs E. van Mens, Saskia Middeldorp   +4 more
doaj   +2 more sources

Direct oral anticoagulants in cancer-associated venous thromboembolism: trial robustness and clinical trade-offs [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Although direct oral anticoagulants (DOACs) are often favored over low-molecular-weight heparin for cancer-associated thrombosis, the robustness of trial evidence supporting their use remains uncertain.
Marco Zuin, Cecilia Becattini, Maria Cristina Vedovati, Jean M. Connors, Gregory Piazza   +4 more
doaj   +2 more sources

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Low-molecular-weight heparins (LMWHs) are widely used in the treatment of cancer-associated venous thromboembolism (VTE), yet their long-term safety profiles remain insufficiently compared in clinical practice. Objectives: The primary outcome
Manuel Monreal, Benjamin Brenner, Covadonga Gómez-Cuervo, Najib Dally, Alicia Alda-Lozano, María Lourdes Pesce, Joaquín Alfonso-Megido, Jacinto Hernández-Borge, Raphael L.E. Mao, Paolo Prandoni, Raquel Barba, Peter Verhamme, Hugo Hyung Bok Yoo, Radovan Malý, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Pierpaolo Di Micco, Abilio Reis, Marijan Bosevski, Lucia Mazzolai, Joseph A. Caprini, Hanh My Bui, A. Abad-Fernández, M.D. Adarraga, J. Aibar, A. Alda, J. Alfonso, C. Amado, M. Angelina-García, J.I. Arcelus, A. Ballaz, R. Barba, C. Barbagelata, M. Barrón, B. Barrón-Andrés, F. Beddar-Chaib, Á. Blanco-Molina, C.S. Bonavila, L. Chasco, G. Claver, P. Crecente, J. Criado, C. De Juana-Izquierdo, J. Del Toro, N. Delgado-Casado, P. Demelo-Rodríguez, M.C. Díaz-Pedroche, J.A. Díaz-Peromingo, Á. Dubois-Silva, D. Durán, J.C. Escribano, L.A. Fernández-Bermejo, C. Fernández-Capitán, J.L. Fernández-Reyes, M.Á. Fidalgo, M. Fuentes Spínola, C. Gabara, F. Galeano-Valle, A. García-Ortega, O. Gavín-Sebastián, A. Gil-Díaz, C. Gómez-Cuervo, J. González Martínez, A. González-Munera, J. Gorostidi-Pérez, L. Guirado, J. Gutiérrez-Guisado, L. Hernández-Blasco, J. Hernández-Borge, M.J. Hernández-Vidal, D. Jiménez, M.D. Joya, A. Lalueza, R. Lecumberri, P. Llamas, H. López-Brull, L. López-Jiménez, P. López-Miguel, J.J. López-Núñez, A. López-Ruiz, J.B. López-Sáez, A. Lorenzo, A. Maestre, P.J. Marchena, M. Marcos, R. Marín-Baselga, M. Martín-del Pozo, M.I. Mercado, J. Moisés-Lafuente, M. Monreal, L. Monzón, S. Moreno-Casas, A. Moreno-Fernández, M.S. Navas, J.A. Nieto, M.J. Núñez-Fernández, M. Olid, M.C. Olivares, J.L. Orcastegui, L. Ordieres-Ortega, M. Ortiz, J. Osorio, S. Otálora, J. Pagán, P. Parra-Caballero, P. Parra-Rosado, J.M. Pedrajas, C. Pérez-Ductor, M. Pérez-Pinar, M.L. Peris, M.L. Pesce, J.A. Porras, L.M. Prieto-Gañán, G. Puche, A. Rivas, F. Rivera-Cívico, A. Rivera-Gallego, A. Rodríguez-Cobo, P. Ruiz-Artacho, N. Ruiz-Giménez, P. Ruiz-Torregrosa, G. Salgueiro, T. Sancho, V. Sendín, G. Sierra-Palomares, A. Solé, S. Soler, S. Suárez-Fernández, R. Tascón-Rodríguez, R. Tirado, M.R. Toda, C. Tolosa, J. Trujillo-Santos, L. Tudela, Y. Tung-Chen, F. Uresandi, R. Valle, J.F. Varona, E. Vega-Romero, D. Vicente-Navarro, G. Vidal, P. Villares, J.S. You, C. Ay, S. Nopp, I. Pabinger, M. Erard, Q. Van Thillo, P. Verhamme, A.T. Rocha, H.H.B. Yoo, C.A. Jiménez-Echandía, A.C. Montenegro, J. Roa, P. Grenar, J. Hirmerova, R. Malý, S. Accassat, L. Bertoletti, A. Bura-Riviere, J. Catella, R. Chopard, F. Couturaud, O. Espitia, R. Le Mao, B. Leclercq, I. Mahé, L. Plaisance, G. Poenou, I. Quéré, G. Sarlon-Bartoli, P. Suchon, E. Versini, S. Schellong, Y. Jenab, A. Khodayari, F. Rashidi, P. Sadeghipour, S. Yadangi, B. Brenner, N. Dally, I. Tzoran, M. Basaglia, F. Bilora, D. Bissacco, C. Bortoluzzi, M. Bortoluzzi, B. Brandolin, R. Casana, M.M. Ciammaichella, P. Di Micco, E. Imbalzano, D. Lambertenghi-Deliliers, R. Pesavento, V. Pizzuti, P. Prandoni, P. Scarinzi, C. Siniscalchi, A. Visonà, N. Vo Hong, B. Zalunardo, A. Skride, L.F. Hernández-Rivera, M.Á. Mendoza Romo-Ramírez, M. Molina-Avilés, Z. Tazi-Mezalek, S. Fonseca, C. Fontes, J. Meireles, B. Soeiro, M. Bosevski, S. Barco, L. Mazzolai, D.J. Angiolillo, J.A. Caprini, L. Ortega-Paz, A.J. Tafur, H.M. Bui, S.T. Nguyen, K.Q. Pham, G.B. Tran   +221 more
doaj   +2 more sources

Low molecular weight heparin-induced thrombocytopenia management during hemodialysis and cardiac surgery: a case report and literature review [PDF]

JA Clinical Reports
Background Heparin-induced thrombocytopenia (HIT) is a serious complication of heparin therapy, including low molecular weight heparins (LMWHs) like dalteparin.
Shuto Takada, Shogo Suzuki, Takahiro Tamura   +2 more
doaj   +2 more sources

Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome [PDF]

Kidney Medicine
Rationale & Objective: Venous thromboembolism is a serious complication of nephrotic syndrome (NS). Guidelines recommend prophylactic anticoagulation with warfarin or low molecular weight heparin.
Sarah Kelddal, Erik L. Grove, Camilla L. Duus, Louis B. Nygaard, Tilde Kristensen, Frank H. Mose, Jon W. Gregersen, Anne-Mette Hvas, Henrik Birn   +8 more
doaj   +2 more sources

Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system [PDF]

Scientific Reports
Venous thromboembolism (VTE) remains a significant global health burden, particularly in older adults. While fondaparinux sodium, enoxaparin sodium, and dalteparin sodium are commonly used anticoagulants, their safety profiles require further evaluation.
Bo-wen Lu, Jia-cheng Li, Ming-tao Wen, Di Luo, Yu-qi Guo, Gang Li   +5 more
doaj   +2 more sources

Comparative analysis of the effects of dalteparin and reviparin on perioperative blood loss in patients with extracapsular hip fractures treated with intramedullary nailing [PDF]

Medicinski Glasnik, 2023
Aim To determine differences between reviparin and dalteparin treatment in patients with extracapsular hip fractures treated with intramedullary nailing and their effects on perioperative blood loss and early postoperative recovery.
Mirza Sivro, Faruk Lazović, Ðemil Omerović, Tarik Kapidžić, Adnan Papović, Mirza Omerčević, Harun Selimović   +6 more
doaj   +1 more source

Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin [PDF]

Journal of the Serbian Chemical Society, 2009
The interaction between trypsin, a prototype S1 serine protease, with heparin and its low molecular weight derivative dalteparin were investigated. Direct inhibition of the proteolytic activity of trypsin by heparin and dalteparin, used in concentrations
OLIVERA M. BOSNIĆ, KRISTINA R. GOPČEVIĆ, MIROSLAV M. VRVIĆ, IVANKA M. KARADŽIĆ   +3 more
doaj   +3 more sources

Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis

Medicina, 2023
Background and Objectives: Venous thromboembolism (VTE) is common in cancer patients. Anticoagulant therapy with low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs), such as dalteparin and apixaban, have demonstrated efficacy and
Miguel A. Arce-Huamani, Joshuan J. Barboza, José Fabián Martínez-Herrera, J. Smith Torres-Roman, Jorge L. Maguiña   +4 more
doaj   +1 more source